Medical researchers have known for more than 50 years that cold can be an important cardio- and neuroprotectant, but concerns about the side effects of deep hypothermia and sloppy, time-consuming procedures turned physicians away. Advances in device design as well as new research on the value of mild hypothermia have unlocked the potential of the therapy to function as a temperature management tool in surgery and critical care, to protect against injury from emboli in cardiac surgery, in resuscitation and trauma, and perhaps the biggest opportunities, in stroke and heart attacks.
by David Cassak
As noted, physicians and medical researchers have been touting the value of cold therapy for more than 50 years. Indeed,...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
